Corpus ID: 20763934

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

@article{Simonson1997EfficacySA,
  title={Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.},
  author={D. Simonson and I. Kourides and M. Feinglos and H. Shamoon and C. Fischette},
  journal={Diabetes care},
  year={1997},
  volume={20 4},
  pages={
          597-606
        }
}
  • D. Simonson, I. Kourides, +2 authors C. Fischette
  • Published 1997
  • Medicine
  • Diabetes care
  • OBJECTIVE To investigate the efficacy, safety, and dose-response characteristics of an extended-release preparation of glipizide using the gastrointestinal therapeutic system (GITS) on plasma glucose, glycosylated hemoglobin (HbA1c), and insulin secretion to a liquid-mixed meal in NIDDM patients. RESEARCH DESIGN AND METHODS Two prospective, randomized, double-blind, placebo-controlled, multicenter clinical trials were performed in 22 sites and 347 patients with NIDDM (aged 59 +/- 0.6 years… CONTINUE READING
    Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
    • 988
    • PDF
    Oral Antihyperglycemic Therapy for Type 2 Diabetes
    • 53
    • PDF
    Clinical review of glimepiride
    • 44